Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

Gautam Borthakur, Jorge E. Cortes, Elihu E. Estey, Elias Jabbour, Stefan Faderl, Susan O'Brien, Guillermo Garcia-Manero, Tapan Mahendra Kadia, Xuemei Wang, Keyur Patel, Rajyalakshmi Luthra, Charles Koller, Mark Brandt, Farhad Ravandi, Hagop Kantarjian

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Despite being considered "good-risk" acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.

Original languageEnglish (US)
Pages (from-to)964-968
Number of pages5
JournalAmerican Journal of Hematology
Volume89
Issue number10
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this

    Borthakur, G., Cortes, J. E., Estey, E. E., Jabbour, E., Faderl, S., O'Brien, S., Garcia-Manero, G., Kadia, T. M., Wang, X., Patel, K., Luthra, R., Koller, C., Brandt, M., Ravandi, F., & Kantarjian, H. (2014). Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. American Journal of Hematology, 89(10), 964-968. https://doi.org/10.1002/ajh.23795